Executive Director of Business Development, Amgen
Syed Kazmi is the Executive Director of Business Development for Amgen based in Thousand Oaks, California. In this role, Syed focuses on corporate mergers and acquisitions, global licensing and strategic collaborations in key therapeutic areas and serves as the Head of International Business Development for Amgen. He played a key role in the acquisition of Onyx Pharmaceuticals by Amgen for over $10B in 2013, executed multiple global oncology licensing transactions and led regional strategic collaboration deals in emerging markets.
Prior to joining Amgen in 2012, Syed served as Vice President, Business Development & Strategic Planning at Ligand Pharmaceuticals for five years. At Ligand he executed multiple acquisitions of public and private companies as well as licensing/strategic collaboration transactions with both large pharma and biotech companies.
Prior to joining Ligand, Syed worked at Johnson & Johnson for 8 years where his most recent position was Principal Scientist in endocrinology and inflammation drug development programs. He held his postdoctoral research positions at McMaster University, Hamilton. Syed received a Ph.D. in biochemistry from J.N. University, New Delhi, and an executive MBA from San Diego State University